StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.50−0.33 (-8.62%)

Close on Nov 17, 2026Market cap $71.86KP/E –Yield –

Addex Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

For fiscal 2025 it was -9390.8%, against -681.8% the year before. The highest annual figure on record is -23.6% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-9390.8%−8708.9
FY2024Dec 31, 2024-681.8%−542.8
FY2023Dec 31, 2023-139.1%+602.0
FY2022Dec 31, 2022-741.0%−209.3
FY2021Dec 31, 2021-531.7%−192.8
FY2020Dec 31, 2020-338.9%+189.7
FY2019Dec 31, 2019-528.6%−505.0
FY2018Dec 31, 2018-23.6%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2024Jun 30, 2024-780.1%–
Q2 FY2023Jun 30, 2023-403.7%–
Q2 FY2022Jun 30, 2022-3868.0%–
Q2 FY2021Jun 30, 2021-454.0%–

More Addex Therapeutics figures

See a number that looks wrong?